ChemicalBook
Chinese Japanese Germany Korea

Imatinib

Product description Approved indications in Europe, the United States and other countries Precautions Uses
Imatinib
Imatinib structure
CAS No.
152459-95-5
Chemical Name:
Imatinib
Synonyms
IMA-3;Veenat;ST-1571;matinib;CS-1955;IMATINIB;CGP057148B;AKOS 91378;IMatinib-D4;IMATINIB-D3
CBNumber:
CB7370890
Molecular Formula:
C29H31N7O
Formula Weight:
493.6
MOL File:
152459-95-5.mol

Imatinib Properties

Melting point:
208-210°C (dec.)
Density 
1?+-.0.06 g/cm3(Predicted)
storage temp. 
Keep in dark place,Sealed in dry,Store in freezer, under -20°C
pka
pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52(at 25℃)
Merck 
14,4902
CAS DataBase Reference
152459-95-5(CAS DataBase Reference)
FDA UNII
BKJ8M8G5HI
ATC code
L01EA01
SAFETY
  • Risk and Safety Statements
Safety Statements  24/25
RTECS  CV5585673
HS Code  29339900

Imatinib price More Price(48)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich Y0001691 Imatinib mesilate European Pharmacopoeia (EP) Reference Standard 152459-95-5 $190 2021-12-16 Buy
TCI Chemical I0906 Imatinib >98.0%(HPLC) 152459-95-5 100mg $52 2021-12-16 Buy
TCI Chemical I0906 Imatinib >98.0%(HPLC) 152459-95-5 1g $154 2021-12-16 Buy
AstaTech 63169 IMATINIB 97% 152459-95-5 1 / G $95 2021-12-16 Buy
Usbiological 452218 Imatinib 152459-95-5 100mg $305 2021-12-16 Buy

Imatinib Chemical Properties,Uses,Production

Product description

Imatinib is a kind of oral drugs used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. CML is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months.
Imatinib is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.

Approved indications in Europe, the United States and other countries

Novartis's imatinib (imatinib, Glivec) had been approved in Switzerland for being used as first-line drug for the treatment of early-stage adult chronic myelogenous leukemia and can also be applied to patients with various types of chronic granulocytic leukemia. Switzerland is the first countries which had approved to additionally include the above two indications of this drug.
On July 28, 2006, the European Agency for the Evaluation of Medicinal Products (EMEA) had recommended the imatinib (Gleevec) of the Novartis Company for the treatment of two new indications-dermatofibrosarcoma protuberans (DFSP) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). These final approvals of these two indications still need to wait the decision of the European Food and Drug Administration.
In addition, Novartis has announced that the application of imatinib in treating hypereosinophilic syndrome and systemic mastocytosis is still in the approval process of FDA and EMEA.
The drug has currently been approved in Europe, the United States and other countries for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph + CML) and gastrointestinal stromal tumors.
The above information is edited by the Chemicalbook of Dai Xiongfeng.

Precautions

When combined with Ketoconazole, itraconazole, erythromycin, clarithromycin, the Cmax of this drug can (the maximum plasma concentration after the first drug administration) be increased by an average of 26% with the AUC being increased by 40%.
The inducers of the metabolizing enzyme of hepatic drugs such as dexamethasone, phenytoin, carbamazepine, rifampicin and barbiturates can significantly reduce blood concentration of the drug.
When the CYP3A4 metabolized substrates such as simvastatin, cyclosporine, pimozide, etc. were used in combined with imatinib, the plasma concentration of those drugs can be increased due to its competing with the drug enzyme.

Uses

Imatinib can be used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon.

Chemical Properties

Orange Solid

Uses

Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib

Uses

antineoplastic

Uses

atypical antipsychotic

Uses

Imatinib impurity.

Indications

Bcr-Abl inhibitor imatinib (Gleevec(R), Novartis) was approved in 2001 by the FDA. Although fasudil was approved in 1995, imatinib is widely perceived as the first approved SMKI mainly owing to the fact that fasudil's kinase inhibitory mechanism was unknown at the time of approval, and efforts to gain approval of fasudil have been unsuccessful in the United States and Europe.
The field of kinase inhibitor development has evolved rapidly since the approval of imatinib. Some of the key discoveries and events include (i) the discovery of MAPK/ERK inhibitors, for example, CI-1040 (PD184352), as the first series of type III inhibitors in 2003; (ii) the approval of first dual tyrosine kinase and serine/threonine kinase inhibitor sorafenib in 2005; (iii) the description of the first series of allosteric type IVkinase inhibitor, that is,GNF-2 and analogues that inhibit Bcr–Abl through an allosteric non-ATP-competitivemode, by Gray and coworkers in 2006; (iv) the approval of the first type III inhibitor trametinib in 2013; (v) the approval of the first covalent kinase inhibitors, afatinib and ibrutinib, in 2013; and (vi) the approval of the first lipid kinase inhibitor, that is, the PI3K inhibitor idelalisib, in 2014.
By December 2016, kinase inhibitor drug discovery can leverage the structures of over 200 human kinases and 5000 kinases of all types, over 1 million publications, clinical data from more than 200 molecules currently in phase I–III trials, and post-marketing results from the approved 38 drugs.

Indications

Imantinib mesylate (Gleevec) is a rationally designed inhibitor of the tumor-specific bcr-abl kinase. The Philadelphia chromosome, present in nearly all patients with chronic myelogenous leukemia (CML), is produced by a chromosomal rearrangement linking the bcr and the abl genes. The bcr-able kinase is therefore a unique drug target in leukemic cells, and imantinib selectively and potently inhibits this kinase. Remissions in CML patients are achieved with high frequency and very low toxicity, and this compound may become a front-line agent for treating this cancer. Unfortunately, drug resistance has already been observed in the clinic as a result of mutations in the bcr-abl kinase, and this magic bullet does not appear to be curative for CML patients. Extension of the use of imantinib to other tumor types with overexpression of c-kit kinase or platelet-derived growth factor kinase is undergoing development because of its observed activity against these kinases.

Imatinib Preparation Products And Raw materials

Raw materials

Preparation Products


Imatinib Suppliers

Global( 450)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86(0)13336195806 +86-571-85586718
+86-571-85864795 sales@capotchem.com China 20012 60
Beijing Cooperate Pharmaceutical Co.,Ltd
010-60279497
010-60279497 sales01@cooperate-pharm.com CHINA 1817 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com China 22607 55
Hangzhou FandaChem Co.,Ltd.
008615858145714
+86-571-56059825 fandachem@gmail.com CHINA 9107 55
Guangzhou PI PI Biotech Inc
+8618371201331
020-81716319 sales@pipitech.com;87478684@qq.com China 3283 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 E-mail:sales03@shyrchem.com
+86-21-34979012 sales03@shyrchem.com CHINA 739 60
Hubei XinRunde Chemical Co., Ltd.
+8615102730682
02783214688 bruce@xrdchem.cn CHINA 567 55
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 26782 60
career henan chemical co
+86-0371-55982848
sales@coreychem.com China 29954 58
Klong Industrial Co., Ltd
0086-519-68231162
info@klongchem.com CHINA 131 58

View Lastest Price from Imatinib manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2021-12-01 Imatinib Raw
152459-95-5
US $19.10 / KG 1KG 99% 10 ton Hebei Crovell Biotech Co Ltd
2021-11-04 Imatinib
152459-95-5
US $0.00 / Kg/Bag 1KG 99%min 100kg WUHAN FORTUNA CHEMICAL CO., LTD
2021-10-08 imatinib
152459-95-5
US $0.00-0.00 / g 1g 98% 100kgs Wuhan Nutra Biotechnology Co.,Ltd

152459-95-5(Imatinib)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved